| scholarly article | Q13442814 |
| P50 | author | Brandie D Wagner | Q46190894 |
| Edith T Zemanick | Q59210801 | ||
| P2093 | author name string | Scott D Sagel | |
| Margaret M Anthony | |||
| Peggy Emmett | |||
| P2860 | cites work | Biochemical and pathologic evidence for proteolytic destruction of lung connective tissue in cystic fibrosis | Q69907533 |
| Elastin and collagen degradation products in urine of patients with cystic fibrosis | Q71842481 | ||
| Sputum peroxidase activity correlates with the severity of lung disease in cystic fibrosis | Q72060753 | ||
| Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation | Q72105394 | ||
| alpha 1-Proteinase inhibitor, elastase activity, and lung disease severity in cystic fibrosis | Q72647013 | ||
| Predictors of deterioration of lung function in cystic fibrosis | Q74054944 | ||
| Induced sputum inflammatory measures correlate with lung function in children with cystic fibrosis | Q78599646 | ||
| alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients | Q79271331 | ||
| Prolastin aerosol therapy and sputum taurine in cystic fibrosis | Q80300248 | ||
| Genetic modifiers of lung disease in cystic fibrosis | Q81316734 | ||
| Pulmonary function is negatively correlated with sputum inflammatory markers and cough clearability in subjects with cystic fibrosis but not those with chronic bronchitis | Q83310445 | ||
| Sputum induction in routine clinical care of children with cystic fibrosis | Q84568150 | ||
| 17beta-Estradiol inhibits Ca2+-dependent homeostasis of airway surface liquid volume in human cystic fibrosis airway epithelia | Q22306299 | ||
| High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis | Q24545304 | ||
| Random-effects models for longitudinal data | Q28279619 | ||
| Standardization of Spirometry, 1994 Update. American Thoracic Society | Q29547574 | ||
| Analysis of left-censored longitudinal data with application to viral load in HIV infection | Q30819879 | ||
| Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection | Q34058988 | ||
| Mixed models for longitudinal left-censored repeated measures | Q35769431 | ||
| Sputum biomarkers of inflammation in cystic fibrosis lung disease | Q36891552 | ||
| Potential role of high-mobility group box 1 in cystic fibrosis airway disease. | Q36935244 | ||
| Association between pulmonary function and sputum biomarkers in cystic fibrosis | Q37287157 | ||
| Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine | Q37822219 | ||
| Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction | Q43796663 | ||
| Levels of free granulocyte elastase in bronchial secretions from patients with cystic fibrosis: effect of antimicrobial treatment against Pseudomonas aeruginosa | Q44412123 | ||
| Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis | Q44923126 | ||
| Microbiology of sputum from patients at cystic fibrosis centers in the United States | Q44982403 | ||
| Pulmonary function between 6 and 18 years of age. | Q46340194 | ||
| Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis | Q46863950 | ||
| Induced sputum matrix metalloproteinase-9 correlates with lung function and airway inflammation in children with cystic fibrosis | Q47870081 | ||
| Longitudinal relationship among growth, nutritional status, and pulmonary function in children with cystic fibrosis: analysis of the Cystic Fibrosis Foundation National CF Patient Registry. | Q50664409 | ||
| Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. | Q51745373 | ||
| Effect of Treatment with Dornase Alpha on Airway Inflammation in Patients with Cystic Fibrosis | Q61791581 | ||
| Sputum and serum calprotectin are useful biomarkers during CF exacerbation | Q64450091 | ||
| Aerosol α1 -antitrypsin treatment for cystic fibrosis | Q68291975 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | inflammation | Q101991 |
| cystic fibrosis | Q178194 | ||
| sputum | Q259346 | ||
| biomarker | Q864574 | ||
| P304 | page(s) | 857-865 | |
| P577 | publication date | 2012-08-16 | |
| P1433 | published in | American Journal of Respiratory and Critical Care Medicine | Q4744267 |
| P1476 | title | Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis | |
| P478 | volume | 186 |
| Q33799602 | 2-O, 3-O-desulfated heparin inhibits neutrophil elastase-induced HMGB-1 secretion and airway inflammation |
| Q39818504 | A comparison of change point models with application to longitudinal lung function measurements in children with cystic fibrosis. |
| Q51710623 | A new player in the game: epithelial cathepsin S in early cystic fibrosis lung disease. |
| Q40996531 | A secretory leukocyte protease inhibitor variant with improved activity against lung infection |
| Q38555389 | A survey of state-of-the-art surface chemistries to minimize fouling from human and animal biofluids |
| Q96231866 | Airway microbial diversity is decreased in young children with cystic fibrosis compared to healthy controls but improved with CFTR modulation |
| Q39097168 | Airway mucus, inflammation and remodeling: emerging links in the pathogenesis of chronic lung diseases |
| Q35104023 | Airway, but not serum or urinary, levels of YKL-40 reflect inflammation in early cystic fibrosis lung disease |
| Q47786141 | Another Brick in the Wall: Lung Clearance Index and Lower Airways Pathology in Preschool Cystic Fibrosis. |
| Q33836925 | Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection |
| Q35127881 | Assessment of airway microbiota and inflammation in cystic fibrosis using multiple sampling methods |
| Q37615212 | Automated CT scan scores of bronchiectasis and air trapping in cystic fibrosis |
| Q41428470 | Azithromycin use in patients with cystic fibrosis |
| Q39240791 | Biofilms and host response - helpful or harmful |
| Q38755600 | Biomarkers for cystic fibrosis drug development |
| Q47196264 | Biomarkers of inflammation in infants with cystic fibrosis |
| Q47265056 | C-reactive protein/albumin ratio is associated with lung function among children/adolescents with cystic fibrosis: a three-year longitudinal study. |
| Q90656732 | Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation |
| Q89157075 | Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis |
| Q47699381 | Chemoattractants and cytokines in primary ciliary dyskinesia and cystic fibrosis: key players in chronic respiratory diseases |
| Q35546970 | Cholesteryl esters are elevated in the lipid fraction of bronchoalveolar lavage fluid collected from pediatric cystic fibrosis patients |
| Q34480471 | Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis |
| Q38669996 | Clinically Promising Biomarkers in Cystic Fibrosis Pulmonary Exacerbations |
| Q35862436 | Complement Effectors of Inflammation in Cystic Fibrosis Lung Fluid Correlate with Clinical Measures of Disease |
| Q36302426 | Complement effectors, C5a and C3a, in cystic fibrosis lung fluid correlate with disease severity |
| Q35741301 | Correlations of salivary biomarkers with clinical assessments in patients with cystic fibrosis |
| Q38911644 | Cystic Fibrosis: Microbiology and Host Response |
| Q33810485 | Cystic fibrosis airway secretions exhibit mucin hyperconcentration and increased osmotic pressure |
| Q36135733 | Cystic fibrosis-adapted Pseudomonas aeruginosa quorum sensing lasR mutants cause hyperinflammatory responses. |
| Q30251439 | Cystic fibrosis. |
| Q38193861 | Defining severity in non-cystic fibrosis bronchiectasis |
| Q33688123 | Early childhood lung function is a stronger predictor of adolescent lung function in cystic fibrosis than early Pseudomonas aeruginosa infection. |
| Q41431296 | Genetic Deletion and Pharmacological Inhibition of PI3K γ Reduces Neutrophilic Airway Inflammation and Lung Damage in Mice with Cystic Fibrosis-Like Lung Disease |
| Q64982979 | Getting Our Fingers on the Pulse of Slow-Growing Bacteria in Hard-To-Reach Places. |
| Q98177430 | Glycosaminoglycans as Multifunctional Anti-Elastase and Anti-Inflammatory Drugs in Cystic Fibrosis Lung Disease |
| Q55297570 | Heparin-binding protein in sputum as a marker of pulmonary inflammation, lung function, and bacterial load in children with cystic fibrosis. |
| Q46308388 | High expression of midkine in the airways of patients with cystic fibrosis |
| Q90731167 | Human Cellular Models for the Investigation of Lung Inflammation and Mucus Production in Cystic Fibrosis |
| Q35618493 | Hypoxic epithelial necrosis triggers neutrophilic inflammation via IL-1 receptor signaling in cystic fibrosis lung disease. |
| Q34973839 | IP-10 is a potential biomarker of cystic fibrosis acute pulmonary exacerbations |
| Q28492950 | Identification of OprF as a complement component C3 binding acceptor molecule on the surface of Pseudomonas aeruginosa |
| Q34784319 | Identification of neutrophil activation markers as novel surrogate markers of CF lung disease |
| Q39100345 | Immunomodulatory indications of azithromycin in respiratory disease: a concise review for the clinician |
| Q40867479 | Infection and inflammation in induced sputum from preschool children with chronic airways diseases |
| Q37727995 | Interactions between Neutrophils and Pseudomonas aeruginosa in Cystic Fibrosis |
| Q34412599 | Lack of neutrophil elastase reduces inflammation, mucus hypersecretion, and emphysema, but not mucus obstruction, in mice with cystic fibrosis-like lung disease |
| Q58609192 | Letting It All Out: Neutrophils in Early CF Airway Inflammation |
| Q92155494 | Lights and Shadows in the Use of Mesenchymal Stem Cells in Lung Inflammation, a Poorly Investigated Topic in Cystic Fibrosis |
| Q40333064 | Mapping air pollution by biological monitoring in the metropolitan Tel Aviv area |
| Q47831284 | Mapping targetable inflammation and outcomes with cystic fibrosis biomarkers. |
| Q35613230 | Mature cystic fibrosis airway neutrophils suppress T cell function: evidence for a role of arginase 1 but not programmed death-ligand 1. |
| Q43144153 | Measurement of serum calprotectin in stable patients predicts exacerbation and lung function decline in cystic fibrosis |
| Q35675928 | Metabolomics analysis identifies novel plasma biomarkers of cystic fibrosis pulmonary exacerbation |
| Q89108036 | Molecular principles for heparin oligosaccharide-based inhibition of neutrophil elastase in cystic fibrosis |
| Q55426892 | Myeloperoxidase as an Active Disease Biomarker: Recent Biochemical and Pathological Perspectives. |
| Q38788006 | Neutrophil Elastase Activity Is Associated with Exacerbations and Lung Function Decline in Bronchiectasis. |
| Q26741691 | Neutrophil elastase and matrix metalloproteinase 12 in cystic fibrosis lung disease |
| Q52721144 | Neutrophil elastase correlates with increased sphingolipid content in cystic fibrosis sputum. |
| Q47108497 | Neutrophil elastase in bronchiectasis. |
| Q45069913 | Neutrophil elastase increases airway ceramide levels via upregulation of serine palmitoyltransferase |
| Q40234482 | Neutrophil extracellular trap release driven by bacterial motility: Relevance to cystic fibrosis lung disease |
| Q47183658 | Neutrophil extracellular traps and the dysfunctional innate immune response of cystic fibrosis lung disease: a review |
| Q64243305 | Neutrophilic proteolysis in the cystic fibrosis lung correlates with a pathogenic microbiome |
| Q38340406 | Novel outcome measures for clinical trials in cystic fibrosis |
| Q45891399 | Oxidative stress in cystic fibrosis patients with Burkholderia cenocepacia airway colonization: relation of 8-isoprostane concentration in exhaled breath condensate to lung function decline |
| Q90176758 | Pf Bacteriophage and Their Impact on Pseudomonas Virulence, Mammalian Immunity, and Chronic Infections |
| Q35164509 | Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease |
| Q37700674 | Phase I Studies of Acebilustat: Biomarker Response and Safety in Patients with Cystic Fibrosis |
| Q89793146 | Postinfectious Bronchiolitis Obliterans in Children: Diagnostic Workup and Therapeutic Options: A Workshop Report |
| Q47788593 | Profile of the ProAxsis active neutrophil elastase immunoassay for precision medicine in chronic respiratory disease |
| Q92132708 | Progress in Model Systems of Cystic Fibrosis Mucosal Inflammation to Understand Aberrant Neutrophil Activity |
| Q63976605 | Prospective multicenter randomized patient recruitment and sample collection to enable future measurements of sputum biomarkers of inflammation in an observational study of cystic fibrosis |
| Q48219744 | Proteomic profiling identifies novel circulating markers associated with bronchiectasis in cystic fibrosis. |
| Q60046880 | Recombinant Heparin-New Opportunities |
| Q33654992 | Release of cystic fibrosis airway inflammatory markers from Pseudomonas aeruginosa-stimulated human neutrophils involves NADPH oxidase-dependent extracellular DNA trap formation |
| Q37631563 | Role of IRE1α/XBP-1 in Cystic Fibrosis Airway Inflammation |
| Q35533349 | Sputum club cell protein concentration is associated with pulmonary exacerbation in cystic fibrosis |
| Q35828811 | Sputum induction improves detection of pathogens in children with cystic fibrosis. |
| Q93105246 | SuFEx-enabled, agnostic discovery of covalent inhibitors of human neutrophil elastase |
| Q58095601 | Targeting Cytokines as Evolving Treatment Strategies in Chronic Inflammatory Airway Diseases |
| Q39971822 | The novel complex allele [A238V;F508del] of the CFTR gene: clinical phenotype and possible implications for cystic fibrosis etiological therapies |
| Q37162991 | Transforming growth factor β1 genotypes in relation to TGFβ1, interleukin-8, and tumor necrosis factor alpha in induced sputum and blood in cystic fibrosis |
| Q33738510 | Update in cystic fibrosis 2012. |
| Q34480433 | miR-31 dysregulation in cystic fibrosis airways contributes to increased pulmonary cathepsin S production |
Search more.